Why Long-Term Investors Should Buy and Hold Intuitive Surgical for Retirement Planning

The question of retirement healthcare expenses looms large for most investors. According to Fidelity data, a 65-year-old retiring in 2025 can expect to spend approximately $172,500 on medical and healthcare costs throughout their retirement years. This substantial figure underscores a fundamental truth: while high healthcare costs burden patients, they create compelling investment opportunities for those seeking long-term wealth building.

One company that has mastered this intersection of healthcare demand and technological innovation is Intuitive Surgical (NASDAQ: ISRG). The firm stands as the undisputed leader in robotic-assisted surgery, and its commitment to integrating artificial intelligence into surgical systems makes it particularly compelling for investors with a buy and hold philosophy spanning decades.

The Market Backdrop: Why Surgical Innovation Matters

The healthcare industry’s scale creates a favorable environment for capital deployment. As medical procedures become increasingly expensive and complex, the demand for efficient, precise interventions grows proportionally. Intuitive Surgical has positioned itself at the epicenter of this transformation through its revolutionary da Vinci robotic platform.

The numbers speak plainly to the company’s penetration: more than 16 million procedures have been performed worldwide using da Vinci systems through 2024. These systems now operate in 72 countries, with over 11,000 installations globally. Every 11.75 seconds, surgeons worldwide commence a procedure using Intuitive’s technology. This establishes the company as the true 800-pound gorilla in its field.

Dominance Through Scale and System Installation

Intuitive Surgical’s competitive moat extends beyond simply selling expensive hardware. The company has architected a revenue model where approximately 75% of earnings derive from servicing, maintenance, and surgical supplies—recurring revenue streams that provide predictable cash flow and strengthen customer lock-in.

Recent expansion efforts demonstrate sustained growth momentum. The company recently obtained regulatory approval to deploy the da Vinci 5 system for certain cardiac procedures, expanding the addressable market for procedures beyond its established base. The newer Ion system, designed for robotic bronchoscopies and lung biopsies, represents an additional revenue frontier.

Financial Performance Justifies Long-Term Positioning

The company’s recent results validate the buy and hold strategy. In its latest quarter reporting, Intuitive Surgical posted worldwide procedure growth of 18% year-over-year, with 532 new da Vinci systems installed compared to 493 in the prior year period. Revenue expanded 19% year-over-year. These expansion rates indicate the company remains in an accelerating growth phase.

Long-term stock performance mirrors this operational strength:

• Past 1 year: 16.88%
• Past 3 years: 26.39% annualized
• Past 5 years: 13.52% annualized
• Past 10 years: 23.86% annualized
• Past 15 years: 18.78% annualized

(Data as of February 2026)

Artificial Intelligence as the Next Frontier

Perhaps most intriguing is Intuitive Surgical’s emerging AI capabilities. The company has accumulated data from over 10 million procedures—an unprecedented dataset for machine learning applications. The company now applies AI to enhance surgical precision continuously.

Consider the Ion system’s latest advancement: AI-powered navigation specifically addresses CT-to-body divergence, a persistent challenge in lung biopsies where target nodules shift position during procedures. Real-time AI correction substantially improves procedural success rates, expanding clinical applications and demonstrating the company’s innovation pipeline remains robust.

Timing Considerations for Entry Points

While the fundamental investment case for a buy and hold position appears sound, valuation deserves consideration. At current levels, Intuitive Surgical’s stock trades at a premium, though valuations have pulled back from previous highs. The company is fairly valued rather than deeply discounted.

Investors should consider three approaches: waiting for pullback opportunities, deploying capital incrementally over time, or entering now with conviction about a multi-decade holding period that accommodates market volatility. The specific tactic matters less than commitment to the long-term thesis.

The Bottom Line

Intuitive Surgical embodies the characteristics of exceptional long-term holdings: dominant market position, durable competitive advantages, recurring revenue streams, and credible AI-driven innovation trajectories. While near-term price action remains uncertain, the fundamental business case for buy and hold investors extends across decades, making it worthy of consideration within any serious retirement portfolio.